journal article Dec 04, 2025

Equity and quality use of medicines in people who present to the Psychiatric Alcohol and Non‐Prescription Drug Assessment Unit

View at Publisher Save 10.1002/bcp.70366
Abstract
Aim
To evaluate quality use of medicines (QUM) in patients admitted to the Psychiatric Alcohol and Non‐Prescription Drug Assessment (PANDA) Unit through analysis of polypharmacy risk, prescribing safety indicators and national QUM indicators.


Methods
Retrospective review of electronic medical records for 787 patients (1245 episodes) admitted to PANDA Unit, St Vincent's Hospital Sydney, November 2020–December 2021. We assessed polypharmacy risk using NSW Therapeutic Advisory Group's Inappropriate Polypharmacy Risk Assessment Tool, evaluated nine prescribing safety indicators (PSIs) and assessed four national quality use of medicines indicators (NQUMIs) in a randomly selected subset of 103 patients.


Results
Mean age was 40.2 years; 67.2% were male. Alcohol‐related diagnoses comprised 32.1% of presentations. Medium‐risk (43.5%) and high‐risk (37.2%) polypharmacy were prevalent, largely reflecting protocol‐driven prescribing for acute presentations. Co‐prescription of QT‐prolonging drugs with antipsychotics affected 17.2% of patients, with 64.7% associated with rapid sedation protocols; only one case of potential QT prolongation was documented. Major gaps were identified in medication reconciliation (40.8% had documented medication history) and discharge documentation (13.1% of discharge summaries contained complete medication information). Patients experiencing homelessness demonstrated poorer outcomes across all QUM indicators, with no discharge summaries meeting quality standards.


Conclusion
While PANDA demonstrated appropriate protocol‐driven prescribing for acute psychiatric presentations, substantial gaps in medication reconciliation and discharge communication highlight challenges in care transitions for priority populations. Standard polypharmacy and prescribing safety indicators may require adaptation for acute psychiatric settings to distinguish appropriate acute prescribing from potentially inappropriate practices.
Topics

No keywords indexed for this article. Browse by subject →

References
30
[5]
Chronic diseases and conditions related to alcohol use

KD Shield

Alcohol Research: Current Reviews 10.35946/arcr.v35.2.06
[6]
Department of Health and Aged Care (2022)
[12]
Australian Commission on Safety and Quality in Health Care, NSW Therapeutic Advisory Group Inc (2014)
[13]
Independent Health and Aged Care Pricing Authority (2022)
[14]
NSW Therapeutic Advisory Group Inc (2020)
[15]
NSW Clinical Excellence Commission (2020)
[16]
(2023)
[17]
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders

Cherrie Galletly, David Castle, Frances Dark et al.

Australian & New Zealand Journal of Psychiatry 10.1177/0004867416641195
Metrics
0
Citations
30
References
Details
Published
Dec 04, 2025
Vol/Issue
92(4)
Pages
1204-1212
License
View
Cite This Article
Jana Stojanova, Elysse Bo Kwan Choy, Jonathan Brett, et al. (2025). Equity and quality use of medicines in people who present to the Psychiatric Alcohol and Non‐Prescription Drug Assessment Unit. British Journal of Clinical Pharmacology, 92(4), 1204-1212. https://doi.org/10.1002/bcp.70366